FDA Updates Congress On CBD Product Labelling Accuracy

FDA Updates Congress On CBD Product Labelling Accuracy

The Food and Drug Administration (FDA) submitted a report to Congress on the state of the CBD marketplace on Wednesday, and the document outlines studies the agency has performed on the contents and quality of cannabis-derived products that it has tested over the past six years. The report, which is responsive to a mandate attached to congressional appropriations legislation last year, shows significant inconsistencies between cannabinoids concentrations that are listed on labels and what the products actually contain. At the same time, it found negligible evidence that dangerous metals and minerals are added to these products. Reform advocates have emphasized the need for FDA to develop regulations to ensure quality control in the market. The agency is in the process of creating those rules, but in the meantime it is generally allowing CBD to be sold while prioritizing enforcement action against companies that make particularly outlandish claims about the medical benefits of their products. “FDA recognizes the significant public interest in CBD products,” the agency wrote. “However, there are many questions about the characteristics of currently marketed CBD products because the Agency lacks significant information on what CBD-containing products are on the market and there are little data available on those products themselves.” “FDA believes that understanding the characteristics of marketed CBD products is critical to making informed decisions about how best to protect public health in the current marketplace,” the report states. While the agency has previously conducted sampling studies for CBD, a spending bill that provided funds for…

Excerpt only …
READ MORE BELOW
Source : MJ moment
Link to original : FDA Updates Congress On CBD Product Labelling Accuracy
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.